Cancer Chemotherapy and Pharmacology

, Volume 56, Issue 6, pp 585–593 | Cite as

Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCδ

  • Keisuke Yamaguchi
  • Mark D. Richardson
  • Darrell D. Bigner
  • Madan M. KwatraEmail author
Original Article


Substance P receptor (SPR), a G protein-coupled receptor (GPCR), is found in human glioblastomas, and has been implicated in their growth. Consistent with a role for SPR in cell growth, activation of SPR in U373 MG human glioblastoma cells leads to the phosphorylation of mitogen-activated protein kinases [extracellular signal-regulated kinase 1 and 2 (ERK1/2)] and stimulation of cell proliferation. The purpose of the present study was to elucidate the pathway through which these actions occur. Using either the epidermal growth factor receptor (EGFR) kinase inhibitor, AG 1478, or a small-interfering RNA (siRNA) directed against human EGFR, we found that transactivation of EGFR by SPR is only marginally involved in SP-dependent ERK1/2 phosphorylation. Src, however, is shown to be a major component of SPR signaling because the Src kinase inhibitor, PP2, and a kinase-dead Src mutant both inhibit SP-dependent ERK1/2 phosphorylation. We also report that SPR stimulates the phosphorylation of protein kinase Cδ(PKCδ), and that this stimulation is blocked by PP2. SP-dependent ERK1/2 phosphorylation is also blocked by rottlerin, a PKCδ inhibitor, and the calcium scavenger, BAPTA/AM. Finally, rottlerin and PP2 were both found to inhibit the growth of several glioblastoma cell lines, underscoring the potential of these agents to block glioblastoma growth.


Substance P receptor Epidermal growth factor receptor (EGFR) Src ERK1/2 Protein kinase C (PKC) Glioblastoma 



Substance P receptor


G protein-coupled receptor


Substance P


Protein kinase C


Extracellular signal-regulated kinase 1 and 2


Epidermal growth factor receptor


1,2-bis-(o-Aminophenoxy)ethane-N, N, N′, N′-tetraacetic acid tetra-(acetoxymethyl) ester


4-Amino-5-(4-chlorphenyl)-7-(tbutyl) pyrazolo[3,4-d]pyrimidine




Epidermal growth factor




Bisindoylmaleimide I



This work was supported in part by National Institutes of Health Grant NS 33405 (to M.M.K.).


  1. 1.
    Otsuka M, Yoshioka K (1993) Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73:229–308PubMedGoogle Scholar
  2. 2.
    Palma C, Maggi CA (2000) The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 67:985–1001PubMedGoogle Scholar
  3. 3.
    Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786–792PubMedGoogle Scholar
  4. 4.
    Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56: 4983–4991PubMedGoogle Scholar
  5. 5.
    Palma C, Nardelli F, Manzini S, Maggi CA (1999) Substance P activates responses correlated with tumour growth in human glioma lines bearing tachykinin NK1 receptors. Br J Pharmacol 79:236–243Google Scholar
  6. 6.
    Palma C, Goso C, Manzini S (1994) Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line. Neurosci Lett 171:221–224PubMedGoogle Scholar
  7. 7.
    Gillespie GY (1996) Cytokines as modulators of malignant glioma progression. In: Ransohoff RM, Beneviste EM (eds) Cytokines and the CNS.CRC Press, Boca Raton, pp 269–286Google Scholar
  8. 8.
    Johnson CL, Johnson CG (1992) Characterization of receptors for substance P in human astrocytoma cells: radioligand binding and inositol phosphate formation. J Neurochem 58:471–477PubMedGoogle Scholar
  9. 9.
    Luo W, Sharif TR, Houghton PJ, Sharif M (1997) CGP 4125 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth Diff 8:1225–1240PubMedGoogle Scholar
  10. 10.
    Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K (2000) The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-κB. J Immunol 165:5606–5611PubMedGoogle Scholar
  11. 11.
    Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K (1997) The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 159:4952–4958PubMedGoogle Scholar
  12. 12.
    Castagliuolo I, Valenick L, Liu J, Pothoulakis C (2000) Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem 275:26545–26550PubMedGoogle Scholar
  13. 13.
    Miller WE, Maudsley S, Ahn S, Khan KD, Luttrell LM, Lefkowitz RJ (2000) β-Arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC. J Biol Chem 275:11312–11319PubMedGoogle Scholar
  14. 14.
    Roush ED, Warabi K, Kwatra MM (1999) Characterization of differences between rapid agonist-dependent phosphorylation and phorbol ester-mediated phosphorylation of human substance P receptor in intact cells. Mol Pharmacol 55:855–862PubMedGoogle Scholar
  15. 15.
    Roush ED, Kwatra MM (1998) Human substance P receptor expressed in Chinese hamster ovary cells directly activates Gαq/11, Gαs, and Gαo. FEBS Lett 428:291–294PubMedGoogle Scholar
  16. 16.
    Pierce KL, Luttrell LM, Lefkowitz RJ (2001) New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20:1532–1539PubMedGoogle Scholar
  17. 17.
    DeFea KA, Vaughn ZD, O’Bryan EM, Nishijima D, Déry O, Bunnett NW (2000) The antiproliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97:11086–11091PubMedGoogle Scholar
  18. 18.
    Traxler P, Bold G, Frei J, Lang N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P (1997) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 40:3601–3616PubMedGoogle Scholar
  19. 19.
    Benes C, Soltoff SP (2001) Modulation of PKCδ tyrosine phosphorylation and activity in salivary and PC-12 cells by Src kinases. Am J Physiol Cell Physiol 280:C1498–C1510PubMedGoogle Scholar
  20. 20.
    Tapia JA, García-Marin LJ, Jensen RT (2003) Cholecystokinin-stimulated protein kinase C-δ kinase activation, tyrosine phosphorylation, and translocation are mediated by Src tyrosine kinases in pancreatic acinar cells. J Biol Chem 278:35220–35230PubMedGoogle Scholar
  21. 21.
    Robin P, Boulven I, Bole-Feysot C, Tanfin Z, Leiber D (2004) Contribution of PKC-dependent and -independent processes in temporal ERK regulation by ET-1, PDGF, and EGF in rat myometrial cells. Am J Physiol Cell Physiol 286:C798–C806PubMedGoogle Scholar
  22. 22.
    Greco S, Muscella A, Elia MG, Romano S, Storelli C, Marsigliante S (2004) Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cell Physiol 201:84–96PubMedGoogle Scholar
  23. 23.
    Treiman M, Caspersen C, Christensen SB (1998) A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca2+-ATPases. Trends Pharmacol Sci 19:131–135PubMedGoogle Scholar
  24. 24.
    Parmer TG, Ward MD, Hait WN (1997) Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Diff 8:327–334PubMedGoogle Scholar
  25. 25.
    Biscardi JS, Tice DA, Parsons SJ (1999) c-Src, receptor tyrosine kinases and human cancer. Adv Cancer Res 76:61–119PubMedGoogle Scholar
  26. 26.
    Staley CA, Parikh NU, Gallick GE (1997) Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Diff 8:269–274PubMedGoogle Scholar
  27. 27.
    Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187–190PubMedGoogle Scholar
  28. 28.
    Susa M, Missbach M, Green J (2000) Src inhibitors: drugs for the treatment of osteoporosis, cancer or both. Trends Pharmacol Sci 21: 489–495PubMedGoogle Scholar
  29. 29.
    Yeatman TJ (2004) A renaissance for Src. Nat Rev Cancer 4: 470–480PubMedGoogle Scholar
  30. 30.
    Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA (1986) Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 261:13754–13759PubMedGoogle Scholar
  31. 31.
    Hussaini IM, Karns LR, Vinton G, Carpenter JE, Redpath GT, Sando JJ, VandenBerg SR (2000) Phorbol 12-myristate 13-acetate induces protein kinase Cη - specific proliferative response in astrocytic tumor cells. J Biol Chem 275:22348–22354PubMedGoogle Scholar
  32. 32.
    Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G, Umansky F, Lorenzo PS, Blumberg PM, Brodie C (2001) Protein kinase Cα and protein kinase Cδ play opposite roles in proliferation and apoptosis of glioma cells. Cancer Res 61:4612–4619PubMedGoogle Scholar
  33. 33.
    Zrachia A, Dobroslav M, Blass M, Kazimirsky G, Kronfeld I, Blumberg PM, Kobiler D, Lustig S, Brodie C (2002) Infection of glioma cells with sindbis virus induces selective activation and tyrosine phosphorylation of protein kinase Cδ. J Biol Chem 277:23693–23701PubMedGoogle Scholar
  34. 34.
    Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmer S, Giafis N, Kalvakolanu DV, Rahman A, Uddin S, Minucci S, Tallman MS, Fish EN, Platanias LC (2003) Activation of protein kinase Cδ by all-trans-retinoic acid. J Biol Chem 278:32544–32551PubMedGoogle Scholar
  35. 35.
    Li W, Jiang Y-X, Zhang J, Soon L, Flechner L, Kapoor V, Pierce JH, Wang L-H (1998) Protein kinase C-δ is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation. Mol Cell Biol 18:5888–5898PubMedGoogle Scholar
  36. 36.
    Jackson DN, Foster DA (2004) The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival. FASEB J 18:627–636PubMedGoogle Scholar
  37. 37.
    Ginnan R, Pfleiderer PJ, Pumiglia K, Singer HA (2004) PKC- and CaMKII-δ2 mediate ATP-dependent activation of ERK1/2 in vascular smooth muscle. Am J Physiol Cell Physiol 286:C1281–C1289PubMedGoogle Scholar
  38. 38.
    Gschwendt M, Müller H-J, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F (1994) Rottlerin, a novel protein kinase inhibitor. Bioch Biochem Biophys Res Commun 199:93–98PubMedGoogle Scholar
  39. 39.
    Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ (2001) Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95: 472–479PubMedGoogle Scholar
  40. 40.
    Efferth T, Ramirez T, Gebhart E, Halatsch ME (2004) Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67:1689–1700PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Keisuke Yamaguchi
    • 1
  • Mark D. Richardson
    • 2
  • Darrell D. Bigner
    • 3
    • 4
  • Madan M. Kwatra
    • 2
    • 4
    • 5
    • 6
    • 2
    Email author
  1. 1.Department of Anesthesiology and Pain MedicineJuntendo University School of MedicineTokyoJapan
  2. 2.Department of AnesthesiologyDuke University Medical CenterDurhamUSA
  3. 3.Department of PathologyDuke University Medical CenterDurhamUSA
  4. 4.Duke Comprehensive Cancer CenterDuke University Medical CenterDurhamUSA
  5. 5.Department of Pharmacology and Cancer BiologyDuke University Medical CenterDurhamUSA
  6. 6.Center for the Study of Aging and Human DevelopmentDuke University Medical CenterDurhamUSA

Personalised recommendations